首例临床应用:99mTc-甲氧基异丁基异腈引导的立体定向乳腺活检
研究回顾性纳入2012年12月至2016年5月共38例连续女性患者,使用基于分子乳腺成像(MBI)的新设备行99mTc-甲氧基异丁基异腈引导的立体定向乳腺病灶活检。38个病灶均技术成功,标本均具放射性且满足组织病理学分析,19个(50%)为恶性,平均操作时间71分钟(范围44-112分钟),37个(97%)成功放置放射学标记,观察到2例血肿和3例血管迷走神经反应。结论认为该技术可行,是乳腺病灶诊断中有价值的补充活检工具。
要点
- 38个病灶均技术成功,活检标本均具放射性且满足组织病理学分析。
- 19个病灶(50%)为恶性,其余为良性。
- 37个病灶(97%)成功放置放射学标记;观察到2例血肿和3例血管迷走神经反应。
核心结论
- 使用专用MBI设备行99mTc-甲氧基异丁基异腈引导的活检技术可行,是乳腺病灶诊断中有价值的补充活检工具。
研究设计与样本
- 回顾性研究,2012年12月至2016年5月连续纳入38例女性患者(平均年龄59岁,范围41-77岁),使用基于MBI的新设备行99mTc-甲氧基异丁基异腈引导的立体定向病灶定位与活检。
临床应用与阅片要点
- 活检分五步:立体定向定位99mTc-甲氧基异丁基异腈高摄取病灶、专用软件计算病灶坐标、置针、验证针位、真空辅助装置取样后于活检部位放置放射学标记并离体测量标本。
- 37个病灶(97%)成功放置放射学标记。
- 平均操作时间71分钟(范围44-112分钟)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of this study is to evaluate a new device using molecular breast imaging (MBI) for 99mTc-sestamibi-guided stereotactic lesion localization as a complementary biopsy tool.
MATERIALS AND METHODS: From December 2012 to May 2016, a total of 38 consecutive women (mean age, 59 years; range, 41-77 years) underwent 99mTc-sestamibi-guided biopsy using a new MBI-based device and were retrospectively reviewed. The biopsy modality used five steps: stereotactic localization of the 99mTc-sestamibi-avid lesion, calculation of coordinates of the lesion location using dedicated software, placement of the needle, verification of the correct needle position, and tissue sampling with a vacuum-assisted device followed by placement of a radiologic marker at the biopsy site and ex vivo measurement of the biopsy specimens.
RESULTS: The procedure was technically successful in all 38 lesions. In all cases, biopsy samples were radioactive and adequate for histopathologic analysis. Nineteen lesions (50%) were found to be malignant, and the remaining lesions were found to be benign. The mean procedure time was 71 minutes (range, 44-112 minutes). The radiologic marker was successfully deployed in 37 lesions (97%). Two hematomas and three vasovagal reactions were observed.
CONCLUSION: Technetium-99m sestamibi-guided biopsy performed using a dedicated MBI-based device is technically feasible and represents a valuable complementary biopsy tool in breast lesion diagnosis.
引用
- Collarino A, Olmos RAV, Neijenhuis PA, et al. First Clinical Experience Using Stereotactic Breast Biopsy Guided by 99mTc-Sestamibi. AJR Am J Roentgenol. 2017. PMID: 28379735. doi:10.2214/AJR.17.18083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。